The subject of the invention is the preparation method for l-phenyl-2,6- bis(2-hydroxyethyl)imidazo[l,5-c]quinazoline-3,5-dione and l-phenyl-2,6-bis(2- hydroxypropyl)imidazo[l,5-c]quinazoline-3,5-dione in form of a compound with structural formula 1 where R is a hydrogen atom -H or methyl group -CH ₃ respectively, in reactions of l-phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione with formula 2 and oxiranes with formula 3 in form of ethylene oxide for R = -H or propylene oxide for R = CH ₃ respectively which may be used as compounds having potential biological activity, starting compounds in synthesis of medicines or substrates for synthesis of other organic compounds with imidazoquinoline ring.

Preparation methods for bis- substituted derivatives of 2H,6H-imidazo[l,5- c]quinazoline, including l-phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione, in reactions with ethylene oxide and propylene oxide in presence of acid or basic catalysts has not yet been disclosed in any patent description. The only information that can be found include synthesis of derivatives of other compounds with imidazoquinoline unit, such as in the publication of patent description No WO2009138796A2 (and the following analogues: EP2297159B1, CN102066379A, RU2010151143A, AU2009247797A1, CA2723858A1, US2011152298A1, KR20110017873 A, JP2011521910A, MX2010012540A, NZ589108A). In the above-mentioned publication, derivatives of imidazo[2, l- b]quinazolin-2-one were obtained and substituted with halogen atoms as well as alkyl, hydroxyl, nitro, cyano, amino or alkoxy groups. In the subsequent publication of the patent description No WO2009138788A1 (and the following analogues: RU2010151142A, AU2009247789A1, CA2723857A1, CN102066341A, EP2297116A1, JP2011520858A, KR20110007247 A, MX2010012541A, NZ589106A, US2011130413A1) and No WO2009138789A1 (and the following analogues: US2011 130405, KR20110006726 A, AU2009247790A1, CA2724213A1, CNl 02076687, JP2011520859A), derivatives of derivatives of anagrelide (6,7-dichloro-l,5-dihydro-imidazo[2,l-b]quinazolin- 2(3H)-one) substituted by groups analogous to imidazo[2, l-b]quinazolin-2-one were obtained. Anagrelide is applied in medicine and pharmacy due to its biological activity. Among the compounds described, the above-mentioned publications however list neither l-phenyl-2,6-bis(2-hydroxyethyl)-6H- imidazo[l,5-c]quinazoline-3,5-dione nor l-phenyl-2,6-bis(2-hydroxypropyl)-6H- imidazo[ 1 , 5-c]quinazoline-3 , 5-dione.

The use of ethylene oxide in the preparation of diols in reaction with heterocyclic compounds with nitrogen atoms was disclosed in publication of British patent description No GB 1290729 A (and the following analogues: GB1290729A, AT293433B, AT296331B, AT298807B, AT300826B, BE741506A, BE750116A4, BE759863A4, BE762253A4, CA920598A1, CA939349A1, CA962680A2, CH521970A, CH523278A, CH523279A, CH525894A, CH549045A, CH552005A, CH552007A, CH557398A, CH559727A5, CS160115B2, CS160116B2, DE1954503A1, DE1966743A1, DE2020091A1, DE2059623A1, DE2104279A1, ES373376A1, ES379472A2, ES385362A1, ES385363A1, ES386181A2, ES387744A2, FR2022997A1, FR2077627A2, FR2080885A2, FR2085582A2, GB1290728A, GB 1291187A, GB1304770A, GB1334461A, GB1334462A, IT954103B, IT989564B, JPS5034031B1, JPS5034032B1, JPS5416508B 1, NL6916903A, NL7006624A, NL7017771A, NL7101233A, SE359544B, SE391924B, SU372815A3, SU398028A3, SU407448A3, SU526288A3, US3629263A, US3631221A, US3772326A, US3828045A, US4060525A, US4161594A, US4227005A, YU245070A, ZA7003049A, ZA7007994A, ZA7100501A). Among the compounds described, the above-mentioned publication does not however list 1- phenyl-2,6-bis(2-hydroxyethyl)-6H-imidazo[l,5-c]quinazoline- 3,5-dione or 1- phenyl-2,6-bis(2-hydroxypropyl)-6H-imidazo[l,5-c]quinazoline -3,5-dione. In these syntheses methods of diols, there is however the need to use excessive amount of oxirane due to very large losses of this substrate in the reaction. Syntheses with use of ethylene oxide with a boiling point of 10.7 °C were conducted under reflux condenser, initially at temperature of 50 ÷ 60 °C and after exothermic effect which occurs during the reaction has subsided at temperature of 90 °C which resulted in evaporating large amount of oxirane used. Preparation method for l-phenyl-2,6-bis(2-hydroxyethyl)imidazo[l,5- c]quinazoline-3,5-dione and l-phenyl-2,6-bis(2-hydroxypropyl)imidazo[l,5- c]quinazoline-3,5-dione in the form of a compound with structural formula 1, where R means hydrogen atom -H or methyl group -CH ₃ respectively, in reactions of l-phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione with formula 2 and oxiranes with formula 3 in form of ethylene oxide for R = -H or propylene oxide for R = -CH ₃ respectively, according to the invention it is characterized by the fact that in the first stage reactions are conducted in pressurized reactor, at a molar ratio of l-phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione to oxirane ratio equal to 1 :2, in solvent and in presence of triethylamine as catalyst, and in the second stage after the reaction is finished, catalyst and solvent are distilled off under reduced pressure. The resulting product is precipitated in acetone and purified by crystallization from ethanol.

Preferably in the first step, in the case of ethylene oxide reactions are conducted at temperature of 60 ÷ 70 °C for at least 70 hours, whereas in the case of propylene oxide it is conducted at temperature of 70 ÷ 90°C for at least 90 hours.

Further benefits are obtained if dimethyl sulfoxide is used as a solvent in the first step, whereas in the second step distillation of the catalyst and solvent is conducted under pressure lower than 10 mm Hg. According to the invention, the preparation process of l-phenyl-2,6-bis(2- hydroxyethyl)imidazo[l,5-c]quinazoline-3,5-dione and l-phenyl-2,6-bis(2- hydroxypropyl)imidazo[l,5-c]quinazolin-3,5-dione consists in reaction of 1- phenyl-2H,6H-imidazo[l,5-c]quinazolin-3,5-dione and oxiranes, such as ethylene oxide and propylene oxide. This reaction is conducted in pressurized reactor at molar ratio of the substrates equal to 1 : 2, in environment of dimethyl sulfoxide, which is the best aprotic solvent of l-phenyl-2H,6H-imidazo[l,5-c]quinazoline- 3,5-dione in the presence of triethylamine as a catalyst. After the reaction is completed, catalyst and solvent are distilled under lowered pressure. The resulting product is precipitatd in acetone and purified by crystallization from ethanol.

The use of pressure reactors allows to conduct the reaction at high temperature without oxirane losses as it occurs in known method described in patent publication No GB1290729A. The use of ethylene oxide and propylene oxide is more beneficial that the use of appropriate chlorohydrins. Reaction with chlorohydrins involves substitution of the chlorine atom through the nitrogen atom of the heterocyclic ring, whereas in basic medium, sodium or potassium chloride is formed in addition to hydroxyalkyl derivatives of azaheterocyclic compounds. However, in the method according to the invention l-phenyl-2H,6H- imidazo[l,5-c]quinazoline-3,5-dione is added to oxiranes, but this reaction does not produce any by-products which have to be removed from the reaction mixture. This eliminates laborious purification of the N-hydroxyalkyl derivatives of 1- phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione from resulting salts in form of sodium or potassium chloride.

Solution according to the invention is further explained in the examples and in the drawing, in which the figures 1,4 and 5 , showing structural formulas, represent l-phenyl-2,6-bis(2-hydroxyethyl)imidazo[l,5-c]quinazoline-3, 5-dione for R = -H and l-phenyl-2,6-bis(2-hydroxypropyl)imidazo[l,5-c]quinazolin-3, 5- dione. Figure 2 represents l-phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione, whereas figure 3 - oxirane in form of ethylene oxide for R = -H and propylene oxide for R = -CH ₃ . The numbers from 1-25 near the symbols of atoms in figures 4 and 5 represent numbers of atoms which were used below in the preparation examples in description of 1H- MR (proton magnetic resonance) and ¹³ C-NMR (carbon magnetic resonance) spectra of the compounds to confirm their structure. Example 1

In the pressurized reactor with capacity of 100 cm ³ , 2.77 g (10 mmol) of 1- phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione, 20 cm ³ of dimethyl sulfoxide, 0.1 g (1 mmol) of triethylamine and 0.88 g (20 mmol) of ethylene oxide were placed. The reaction mixture was stirred with a magnetic stirrer and heated to the temperature of 70°C. Reaction was completed after 70 hours, when collected sample of reaction mixture did not reveal loss in mass on the analytical balance and the epoxide number was zero. DMSO was distilled off under reduced pressure (p = 7 mm Hg, the temperature of the liquid 65 - 110°C, temperature of vapors 68 - 72°C). The resulting products were precipitated with acetone, then drained and purified by crystallization from ethanol.

l-phenyl-2,6-bis(2-hydroxyethyl)imidazo[l,5-c]quinazoline-3, 5-dione with formula 1, where R = -H, was received. Product characteristics: melting point of 217 ÷ 218 ° C; IR (KBr) (IR spectrum made in the form of pellets with potassium bromide), v = 3435 (s, OH valence), 3030 (w, CH, deformation of phenyl ring), 2955 (w, -CH ₂ -, asymmetric valence), 2883 (w, -CH ₂ -, symmetric valence), 1742 (s, C=0, valence), 1053 (m, C-O-H, valence), 1660, 1612, 1509, 1445 (s, skeleton of phenyl ring), 1156 (w, C-H, flat deformation), 752, 699 (s, deformation, non-flat), 1631, 1587, 1485 (s, skeletal of quinazoline ring), 845 (m, deformation) [cm ^"1 ]; 1H- MR (500 MHz, d ₆ -DMSO (deuterated dimethyl sulfoxide)), δ = 3.35 (2 H, t, -N-CH ₂ -, J _20,2 i = 5.51 Hz), 3.47 (2H, t, -CH ₂ -OH, i = 6.24 Hz), 3.64 (2 H, t, -N-CH ₂ -, J _22,23 = 5.51 Hz), 4.10 (2H, t, -CH ₂ -OH, J _22,23 = 6,24 Hz), 4.81 (1 H, t, -OH, J _0,2 i = 5.42 Hz), 4.90 (1 H, t, -OH, J _0,23 = 5.42 Hz), 6.72 (1 H, d, J _8,9 = 8.07 Hz ), 6.80 (1 H, t, Ji _0, n = 7.45 Hz), 7.21 (1 H, t, J _9,8 = 7.25 Hz), 7.29 (1 H, d, Ji _U0 = 8.09 Hz) 7.54 (2 H, m), 7.62 (3 H, m); ¹³ C- MR (de-DMSO), δ = 147.90 (C ₃ ), 145.10 (C ₅ ), 134.79 (C ₇ ), 13 1.05 (C ₁₇ ), 129.94 (C _16> Cig), 129.44 (Cis i Ci ₉ ), 128.26 (CM), 127.88 (C ₉ ), 125.29 (Cn), 122.48 (Cio), 121.13 (C ₈ ), 1 17.75 (Ci), 1 14.01 (Ci ₃ ), 1 1 1.84 (Ci ₂ ), 57.75 (C ₂₁ ), 56.49 (C ₂₃ ), 44.12 (C ₂₂ ), 43.15 (C ₂₀ ), [ppm]; AE (elemental analysis), %N _ca i _cu i _a , _e d = 1 1.57, %Ndetermined- = 1 1.41, %C _ca lculated- = 65.75, %Cdetermined- = 65.60, %H _calcu i _at ed- = 5.24,

%Hdetermined- = 5.08; UV (ultraviolet spectrum), 224, 264, 335 [run]. Example 2

In the pressurized reactor with capacity of 100 cm ³ , 2.77 g (10 mmol) of 1- phenyl-2H,6H-imidazo[l,5-c]quinazoline-3,5-dione, 20 cm ³ of dimethyl sulfoxide, 0.2 g (2 mmol) of triethylamine and 1.16 g (20 mmol) of propylene oxide were placed. The reaction mixture was stirred with a magnetic stirrer and heated to the temperature of 90°C. Reaction was completed after 90 hours, when collected sample of reaction mixture did not reveal loss in mass on the analytical balance and the epoxide number was zero. The next step was the same as in example 1.

l-phenyl-2,6-bis(2-hydroxypropylo)imidazo[l,5-c]quinazoline- 3,5-dione with formula 1, where R = -CH ₃ , was received with capacity of 60%. Product characteristics: melting point of 178 ÷ 179 ° C; IR (KBr), v = 3446 (s, O-H valence), 3032 (w, C-H, valence in the ring), 2954 (w, -CH ₂ -, asymmetric valence), 2882 (w, -CH ₂ -, symmetric valence), 1745 (s, C=0, valence), 1061 (m, C-O-H, valence), 1660, 1612, 1509, 1445 (s, skeleton of phenyl ring), 1 156 (w, C- H, flat deformation), 752, 699 (s, deformation, non-flat), 1631, 1587, 1485 (s, skeletal of quinazoline ring), 845 (m, deformation) [cm ^"1 ]; 1H- MR (500 MHz, de-DMSO), δ = 0.88 (3H, d, CH ₃ , J _22,2 i = 6.42 Hz), 1.35 (3H, d, CH ₃ , J _25,24 = 6.42 Hz), 3.51 (1 H, dd, -N-CH-, J _20A B = 24.64 Hz, J _20A,2 i = 6.98 Hz), 3.56 (1H, dd, - CH-N, J ₂₀ AB = 24.64 Hz, J _20B,2 i = 6.28 Hz), 3.62 (1 H, dd, -N-CH-, J _23AB = 23.73 Hz, J _23A,24 = 8.38 Hz), 3.68 (1H, dd, -CH-N, J _23AB = 23.73 Hz, J _23B,24 = 7.68 Hz), 3.90 (1 H, sept., CH-OH, hi _, n = 6.82 Hz), 4.60 (1 H, sept., CH-OH, J _23;24 = 6.82 Hz), 4.82 (1 H, d, -OH), 4.92 (1 H, d, -OH), 6.75 (1 H, d, Ji _0, ii = 6.16 Hz ), 7.10 (1 H, t, Jio _,9 = 7.86 Hz), 7, 21 (1 H, d, J _9,8 = 7.45 Hz), 7.32 (1 H, t, J _9, io = 7.86 Hz), 7.52 (2 H, m), 7.63 (3 H, m); ¹³ C- MR (d ₆ -DMSO), δ = 148.10 (C ₃ ), 144.81 (C ₅ ), 134.12 (C ₇ ), 131.82 (Cn) 131.00 (Ci ₆ , C _i8 ), 129.81 (Ci ₅ , Ci ₉ ), 129.21 (C _M ), 128.36 (C ₁₃ ), 127.85 (C ₉ ), 122.37 (C ₁₀ ), 120.82 (Cn), 118.21 (Ci), 114.92 (C ₈ ), 112.61 (Ci ₂ ), 64.26 (C ₂₄ ), 63.15 (C ₂₁ ), 49.02 (C ₂₃ ), 47.92 (C ₂₀ ), 20.72 (C ₂₅ ), 20.60 (C ₂₂ ), [ppm]; AE, %N _ca i _c .. = 11.37, %N _de ,erm. = 11.30, %C _ca i _c . = 65.03, %C _de ,erm. = 65.29, %H _ca i _c . = 6.28, %H _de , _e rm. = 6.20.

The invention may be used as compounds having potential biological activity, starting compounds in synthesis of medicines or substrates for synthesis of other organic compounds with imidazoquinazoline ring.